• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一个转化性非酒精性脂肪性肝炎(NASH)小鼠模型中揭示与NASH相关纤维化发病的预测性分子特征。

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.

作者信息

van Koppen Arianne, Verschuren Lars, van den Hoek Anita M, Verheij Joanne, Morrison Martine C, Li Kelvin, Nagabukuro Hiroshi, Costessi Adalberto, Caspers Martien P M, van den Broek Tim J, Sagartz John, Kluft Cornelis, Beysen Carine, Emson Claire, van Gool Alain J, Goldschmeding Roel, Stoop Reinout, Bobeldijk-Pastorova Ivana, Turner Scott M, Hanauer Guido, Hanemaaijer Roeland

机构信息

Department of Metabolic Health Research, TNO, Leiden, The Netherlands.

University Medical Center Utrecht, Utrecht, The Netherlands.

出版信息

Cell Mol Gastroenterol Hepatol. 2017 Oct 14;5(1):83-98.e10. doi: 10.1016/j.jcmgh.2017.10.001. eCollection 2018.

DOI:10.1016/j.jcmgh.2017.10.001
PMID:29276754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5738456/
Abstract

BACKGROUND & AIMS: The incidence of nonalcoholic steatohepatitis (NASH) is increasing. The pathophysiological mechanisms of NASH and the sequence of events leading to hepatic fibrosis are incompletely understood. The aim of this study was to gain insight into the dynamics of key molecular processes involved in NASH and to rank early markers for hepatic fibrosis.

METHODS

A time-course study in low-density lipoprotein-receptor knockout. Leiden mice on a high-fat diet was performed to identify the temporal dynamics of key processes contributing to NASH and fibrosis. An integrative systems biology approach was used to elucidate candidate markers linked to the active fibrosis process by combining transcriptomics, dynamic proteomics, and histopathology. The translational value of these findings were confirmed using human NASH data sets.

RESULTS

High-fat-diet feeding resulted in obesity, hyperlipidemia, insulin resistance, and NASH with fibrosis in a time-dependent manner. Temporal dynamics of key molecular processes involved in the development of NASH were identified, including lipid metabolism, inflammation, oxidative stress, and fibrosis. A data-integrative approach enabled identification of the active fibrotic process preceding histopathologic detection using a novel molecular fibrosis signature. Human studies were used to identify overlap of genes and processes and to perform a network biology-based prioritization to rank top candidate markers representing the early manifestation of fibrosis.

CONCLUSIONS

An early predictive molecular signature was identified that marked the active profibrotic process before histopathologic fibrosis becomes manifest. Early detection of the onset of NASH and fibrosis enables identification of novel blood-based biomarkers to stratify patients at risk, development of new therapeutics, and help shorten (pre)clinical experimental time frames.

摘要

背景与目的

非酒精性脂肪性肝炎(NASH)的发病率正在上升。NASH的病理生理机制以及导致肝纤维化的一系列事件尚未完全明确。本研究旨在深入了解NASH相关关键分子过程的动态变化,并对肝纤维化的早期标志物进行排序。

方法

对低密度脂蛋白受体敲除的莱顿小鼠进行高脂饮食的时间进程研究,以确定导致NASH和纤维化的关键过程的时间动态变化。采用整合系统生物学方法,通过结合转录组学、动态蛋白质组学和组织病理学来阐明与活跃纤维化过程相关的候选标志物。利用人类NASH数据集证实了这些发现的转化价值。

结果

高脂饮食以时间依赖性方式导致肥胖、高脂血症、胰岛素抵抗以及伴有纤维化的NASH。确定了NASH发展过程中关键分子过程的时间动态变化,包括脂质代谢、炎症、氧化应激和纤维化。一种数据整合方法能够使用一种新的分子纤维化特征在组织病理学检测之前识别活跃的纤维化过程。人类研究用于确定基因和过程的重叠,并基于网络生物学进行优先级排序,以对代表纤维化早期表现的顶级候选标志物进行排名。

结论

确定了一种早期预测分子特征,该特征在组织病理学纤维化显现之前就标记了活跃的促纤维化过程。NASH和纤维化发病的早期检测能够识别新的基于血液的生物标志物,以对有风险的患者进行分层,开发新的治疗方法,并有助于缩短(临床前)临床试验时间框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/923d52af8dee/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/3fd64ec4c8c8/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/0d4765f55e1c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/74c8a2ca408e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/7dd3162c9141/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/a307915a5f23/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/6dbb7592b133/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/30b902d6e21d/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/85852904ed35/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/f9db80639172/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/923d52af8dee/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/3fd64ec4c8c8/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/0d4765f55e1c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/74c8a2ca408e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/7dd3162c9141/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/a307915a5f23/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/6dbb7592b133/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/30b902d6e21d/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/85852904ed35/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/f9db80639172/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c2/5738456/923d52af8dee/gr9.jpg

相似文献

1
Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.在一个转化性非酒精性脂肪性肝炎(NASH)小鼠模型中揭示与NASH相关纤维化发病的预测性分子特征。
Cell Mol Gastroenterol Hepatol. 2017 Oct 14;5(1):83-98.e10. doi: 10.1016/j.jcmgh.2017.10.001. eCollection 2018.
2
A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.表达人类病理学关键途径的伴有晚期纤维化和动脉粥样硬化的 NASH 的转化型小鼠模型。
Cells. 2020 Sep 1;9(9):2014. doi: 10.3390/cells9092014.
3
Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.巨噬细胞衍生的血小板反应蛋白1促进肥胖相关的非酒精性脂肪性肝病。
JHEP Rep. 2020 Oct 9;3(1):100193. doi: 10.1016/j.jhepr.2020.100193. eCollection 2021 Feb.
4
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.非酒精性脂肪性肝病全谱的代谢特征
JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.
5
Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis.解析 NASH 发病机制对动脉粥样硬化的转录动力学影响。
Int J Mol Sci. 2022 Jul 26;23(15):8229. doi: 10.3390/ijms23158229.
6
Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.非酒精性脂肪性肝病的自然史:一项配对肝活检研究
J Clin Exp Hepatol. 2020 May-Jun;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002. Epub 2019 Jul 15.
7
Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice.奥贝胆酸调节人类非酒精性脂肪性肝炎特征性的血清代谢物和基因特征,并减轻Ldlr-/-。莱顿小鼠的炎症和纤维化进展。
Hepatol Commun. 2018 Oct 29;2(12):1513-1532. doi: 10.1002/hep4.1270. eCollection 2018 Dec.
8
Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.罗格列酮可减轻雄性低密度脂蛋白受体敲除小鼠的年龄和饮食相关的非酒精性脂肪性肝炎。
Hepatology. 2010 Dec;52(6):2001-11. doi: 10.1002/hep.23941. Epub 2010 Oct 11.
9
Key Inflammatory Processes in Human NASH Are Reflected in Ldlr.Leiden Mice: A Translational Gene Profiling Study.人类非酒精性脂肪性肝炎中的关键炎症过程在载脂蛋白E基因缺陷(Ldlr).Leiden小鼠中得到体现:一项转化基因谱研究。
Front Physiol. 2018 Feb 23;9:132. doi: 10.3389/fphys.2018.00132. eCollection 2018.
10
Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.二十二碳六烯酸可减轻 LDLR(-/-)小鼠模型中由西方饮食诱导的非酒精性脂肪性肝炎的肝炎症、氧化应激和肝纤维化,而不会减少肝脂肪变性。
J Nutr. 2013 Mar;143(3):315-23. doi: 10.3945/jn.112.171322. Epub 2013 Jan 9.

引用本文的文献

1
Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population.TLM3生物标志物组合对普通人群中MAFLD早期纤维化发展的预后价值
Liver Int. 2025 Jul;45(7):e70169. doi: 10.1111/liv.70169.
2
The Non-Canonical ChREBPα Activity Suppresses the Activation of Hepatic Stellate Cells and Liver Fibrosis by Antagonizing TGF-β-E2F1 Axis.非经典ChREBPα活性通过拮抗TGF-β-E2F1轴抑制肝星状细胞激活和肝纤维化。
Adv Sci (Weinh). 2025 Aug;12(29):e15032. doi: 10.1002/advs.202415032. Epub 2025 Jun 23.
3
Fibrogenic Gene Signature as Early Prediction for the Efficacy of Pharmacological Interventions for MASH-Associated Fibrosis.

本文引用的文献

1
Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma.人类肝细胞癌中持续改变的代谢靶点的鉴定
Cell Mol Gastroenterol Hepatol. 2017 May 31;4(2):303-323.e1. doi: 10.1016/j.jcmgh.2017.05.004. eCollection 2017 Sep.
2
The Quest for Relevant Hepatocellular Carcinoma Biomarkers.寻找相关的肝细胞癌生物标志物。
Cell Mol Gastroenterol Hepatol. 2017 Jul 14;4(2):283-284. doi: 10.1016/j.jcmgh.2017.06.003. eCollection 2017 Sep.
3
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
纤维化基因特征作为MASH相关纤维化药物干预疗效的早期预测指标
FASEB J. 2025 Jun 30;39(12):e70735. doi: 10.1096/fj.202500718R.
4
Acyl-CoA Thioesterase 1 Contributes to Transition of Steatosis to Metabolic-Associated Steatohepatitis.酰基辅酶A硫酯酶1促成脂肪变性向代谢相关脂肪性肝炎的转变。
Int J Hepatol. 2024 Jul 11;2024:5560676. doi: 10.1155/2024/5560676. eCollection 2024.
5
Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-/-.Leiden mice.FGF21 类似物 bFKB1 对 Ldlr-/-.Leiden 小鼠中 MASH 和动脉粥样硬化的治疗作用。
FASEB J. 2024 Oct 31;38(20):e70087. doi: 10.1096/fj.202401397R.
6
Integrating text mining with network models for successful target identification: validation in MASH-induced liver fibrosis.将文本挖掘与网络模型相结合以成功进行靶点识别:在MASH诱导的肝纤维化中的验证
Front Pharmacol. 2024 Sep 27;15:1442752. doi: 10.3389/fphar.2024.1442752. eCollection 2024.
7
Purinergic signaling in liver disease: calcium signaling and induction of inflammation.肝病中的嘌呤能信号传导:钙信号传导与炎症诱导
Purinergic Signal. 2025 Feb;21(1):69-81. doi: 10.1007/s11302-024-10044-9. Epub 2024 Sep 25.
8
miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.肝细胞中 miR-33 的缺失可减轻 MASLD-MASH-HCC 的进展。
JCI Insight. 2024 Aug 27;9(19):e168476. doi: 10.1172/jci.insight.168476.
9
Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD.用于 MASLD 肝纤维化的新型无创生物标志物组合的开发。
Nat Commun. 2024 May 29;15(1):4564. doi: 10.1038/s41467-024-48956-0.
10
Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis.肝脂肪变性进展的演变模型、算法及预测参数
Metabolites. 2024 Apr 3;14(4):198. doi: 10.3390/metabo14040198.
非酒精性脂肪性肝病中纤维化阶段导致的死亡风险增加:系统评价与荟萃分析
Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.
4
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.通过测量组织和血液中的细胞外基质重塑率来识别患有活动性纤维化的非酒精性脂肪性肝病患者。
Hepatology. 2017 Jan;65(1):78-88. doi: 10.1002/hep.28860. Epub 2016 Nov 15.
5
Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.比较非酒精性脂肪性肝病小鼠模型和患者肝组织的基因表达谱。
Gastroenterology. 2016 Sep;151(3):513-525.e0. doi: 10.1053/j.gastro.2016.05.051. Epub 2016 Jun 16.
6
An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present.非酒精性脂肪性肝炎小鼠模型概述:从过去到现在
Curr Protoc Mouse Biol. 2016 Jun 1;6(2):185-200. doi: 10.1002/cpmo.3.
7
Non-alcoholic fatty liver disease and dyslipidemia: An update.非酒精性脂肪性肝病与血脂异常:最新进展
Metabolism. 2016 Aug;65(8):1109-23. doi: 10.1016/j.metabol.2016.05.003. Epub 2016 May 13.
8
Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease.代谢健康型肥胖与非酒精性脂肪性肝病的发生发展
Am J Gastroenterol. 2016 Aug;111(8):1133-40. doi: 10.1038/ajg.2016.178. Epub 2016 May 17.
9
Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice.使用半胱天冬酶-1抑制剂进行干预可减轻LDLR-/-。莱顿小鼠的肥胖相关高胰岛素血症、非酒精性脂肪性肝炎和肝纤维化。
Int J Obes (Lond). 2016 Sep;40(9):1416-23. doi: 10.1038/ijo.2016.74. Epub 2016 May 28.
10
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).非酒精性脂肪性肝病(NAFLD)的多重打击发病机制。
Metabolism. 2016 Aug;65(8):1038-48. doi: 10.1016/j.metabol.2015.12.012. Epub 2016 Jan 4.